The high cost and time required for US clinical trials create a rational economic incentive for companies and investors to move operations to China. The solution isn't to match China's low costs, but to significantly improve US efficiency to make domestic investment more competitive.

Pfizer's CEO warns that China's meticulously executed national plan for pharma—improving regulators, strengthening IP, and funding science—is a disruptive force. Operating at half the cost and three times the speed, China is on track to lead in multiple areas of drug discovery within 1-2 years.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

While China is a rising competitor, the real danger to America's biotech leadership is the weakening of its own foundational pillars. Eroding NIH funding, restrictive immigration for top talent, and inefficient regulatory processes pose a greater risk than any single foreign nation.

China is no longer just a low-cost manufacturing hub for biotech. It has become an innovation leader, leveraging regulatory advantages like investigator-initiated trials to gain a significant speed advantage in cutting-edge areas like cell and gene therapy. This shifts the competitive landscape from cost to a race for speed and novel science.

To compete with China's rapid 'me-better' development, U.S. innovators should proactively partner with Chinese firms to create improved versions of their own drugs. This self-cannibalization strategy is necessary to stay ahead before competitors do it for them.

Faced with China's superior speed and cost in executing known science, the U.S. biotech industry cannot compete by simply iterating faster. Its strategic advantage lies in

John Crowley, CEO of Bio, argues the best strategy for US biotech dominance is not protectionism. Instead, the focus should be on improving the US's own competitive advantages, like streamlining regulations and lowering innovation costs, to maintain its lead rather than trying to stifle Chinese research.

The increasing innovation and speed from China puts pressure on the U.S. biotech ecosystem. To remain competitive, the U.S. must focus on collaboration and address its own systemic issues, such as slow trial execution and the high cost of getting a drug to the IND stage.